KRYS
Price
$320.13
Change
-$2.04 (-0.63%)
Updated
Oct 22 closing price
Capitalization
9.48B
10 days until earnings call
Intraday BUY SELL Signals
TGTX
Price
$53.16
Change
-$0.04 (-0.08%)
Updated
Oct 22 closing price
Capitalization
8.14B
10 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

KRYS vs TGTX

KRYS vs TGTX Comparison Chart in %
View a ticker or compare two or three
VS
KRYS vs. TGTX commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KRYS is a Hold and TGTX is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for KRYS with price predictions
Oct 22, 2026

KRYS in downward trend: price dove below 50-day moving average on September 28, 2026

KRYS moved below its 50-day moving average on September 28, 2026 date and that indicates a change from an upward trend to a downward trend. In 31 of 39 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 79%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on KRYS as a result. In 80 of 106 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 75%.

The Moving Average Convergence Divergence Histogram (MACD) for KRYS turned negative on October 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 57 similar instances when the indicator turned negative. In 39 of the 57 cases the stock turned lower in the days that followed. This puts the odds of success at 68%.

The 10-day moving average for KRYS crossed bearishly below the 50-day moving average on September 18, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 63%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where KRYS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 71%.

The Aroon Indicator for KRYS entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 40 of 54 cases where KRYS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.

Following a +2.79% 3-day Advance, the price is estimated to grow further. Considering data from situations where KRYS advanced for three days, in 260 of 327 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

KRYS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is 9 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron PE Growth Rating for this company is 37 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. KRYS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 46 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.972) is normal, around the industry mean (2.973). P/E Ratio (38.710) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (23.202) is also within normal values, averaging (438.009).

A.I.Advisor
a Summary for TGTX with price predictions
Oct 22, 2026

Momentum Indicator for TGTX turns negative, indicating new downward trend

TGTX saw its Momentum Indicator move below the 0 level on October 22, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 80 similar instances where the indicator turned negative. In 70 of the 80 cases, the stock moved further down in the following days. The odds of a decline are at 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for TGTX turned negative on September 29, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 34 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 79%.

TGTX moved below its 50-day moving average on October 21, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for TGTX crossed bearishly below the 50-day moving average on October 21, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 76%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TGTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 56 of 64 cases where TGTX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.

Following a +3.06% 3-day Advance, the price is estimated to grow further. Considering data from situations where TGTX advanced for three days, in 254 of 304 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

TGTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 179 of 210 cases where TGTX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 85%.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 14 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. TGTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 60 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.

The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (13.470) is normal, around the industry mean (2.973). P/E Ratio (17.373) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (11.136) is also within normal values, averaging (438.009).

The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

FUNDAMENTALS RATINGS
KRYS vs TGTX: Fundamental Ratings
KRYS
TGTX
OUTLOOK RATING
1..100
670
VALUATION
overvalued / fair valued / undervalued
1..100
92
Overvalued
90
Overvalued
PROFIT vs RISK RATING
1..100
960
SMR RATING
1..100
4614
PRICE GROWTH RATING
1..100
4242
P/E GROWTH RATING
1..100
3796
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TGTX's Valuation (90) in the Biotechnology industry is in the same range as KRYS (92) in the Pharmaceuticals Major industry. This means that TGTX’s stock grew similarly to KRYS’s over the last 12 months.

KRYS's Profit vs Risk Rating (9) in the Pharmaceuticals Major industry is somewhat better than the same rating for TGTX (60) in the Biotechnology industry. This means that KRYS’s stock grew somewhat faster than TGTX’s over the last 12 months.

TGTX's SMR Rating (14) in the Biotechnology industry is in the same range as KRYS (46) in the Pharmaceuticals Major industry. This means that TGTX’s stock grew similarly to KRYS’s over the last 12 months.

TGTX's Price Growth Rating (42) in the Biotechnology industry is in the same range as KRYS (42) in the Pharmaceuticals Major industry. This means that TGTX’s stock grew similarly to KRYS’s over the last 12 months.

KRYS's P/E Growth Rating (37) in the Pharmaceuticals Major industry is somewhat better than the same rating for TGTX (96) in the Biotechnology industry. This means that KRYS’s stock grew somewhat faster than TGTX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
KRYSTGTX
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
74%
Bullish Trend 1 day ago
88%
Momentum
ODDS (%)
Bearish Trend 1 day ago
75%
Bearish Trend 1 day ago
88%
MACD
ODDS (%)
Bearish Trend 1 day ago
68%
Bearish Trend 1 day ago
79%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
68%
Bearish Trend 1 day ago
82%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
70%
Bearish Trend 1 day ago
80%
Advances
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 8 days ago
84%
Declines
ODDS (%)
Bearish Trend 1 day ago
71%
Bearish Trend 1 day ago
83%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
86%
Aroon
ODDS (%)
Bearish Trend 1 day ago
66%
Bullish Trend 1 day ago
85%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (KRYS: $320.13 vs. TGTX: $53.16)
Brand notoriety: KRYS and TGTX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: KRYS: 91% vs. TGTX: 76%
Market capitalization -- KRYS: $9.48B vs. TGTX: $8.14B
KRYS [@Biotechnology] is valued at $9.48B. TGTX’s [@Biotechnology] market capitalization is $8.14B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $135.64B. The average market capitalization across the [@Biotechnology] industry is $2.14B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KRYS’s FA Score shows that 1 FA rating(s) are green while TGTX’s FA Score has 1 green FA rating(s).

  • KRYS’s FA Score: 1 green, 4 red.
  • TGTX’s FA Score: 1 green, 4 red.
According to our system of comparison, KRYS is a better buy in the long-term than TGTX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KRYS’s TA Score shows that 3 TA indicator(s) are bullish while TGTX’s TA Score has 4 bullish TA indicator(s).

  • KRYS’s TA Score: 3 bullish, 6 bearish.
  • TGTX’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, TGTX is a better buy in the short-term than KRYS.

Price Growth

KRYS (@Biotechnology) experienced а -2.99% price change this week, while TGTX (@Biotechnology) price change was -5.07% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.17%. For the same industry, the average monthly price growth was -18.21%, and the average quarterly price growth was -15.24%.

Reported Earning Dates

KRYS is expected to report earnings on Nov 02, 2026.

TGTX is expected to report earnings on Nov 02, 2026.

Industries' Descriptions

@Biotechnology (-1.17% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
KRYS
Daily Signal:
Gain/Loss:
TGTX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

TGTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, TGTX has been loosely correlated with ARQT. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if TGTX jumps, then ARQT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TGTX
1D Price
Change %
TGTX100%
-0.08%
ARQT - TGTX
39%
Loosely correlated
+1.04%
PTGX - TGTX
38%
Loosely correlated
+1.05%
KRYS - TGTX
37%
Loosely correlated
-0.63%
ARRY - TGTX
36%
Loosely correlated
-3.23%
PTCT - TGTX
36%
Loosely correlated
+0.67%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
BTO37.370.72
+1.96%
John Hancock Financial Opportunities Fund
UPSX9.070.12
+1.34%
Tradr 2X Long UPST Daily ETF (UPSX)
HTAB18.330.17
+0.94%
Hartford Schroders Tax-Aware Bond ETF (HTAB)
KDEC28.110.01
+0.03%
Innovator U.S. Small Cap Power Buffer ETF - December (KDEC)
VOT289.24-4.59
-1.56%
Vanguard Morningstar Mid-Cap Growth ETF (VOT)